Form 8-K

8-K — TELA Bio, Inc.

Accession: 0001104659-26-059393

Filed: 2026-05-12

Period: 2026-05-12

CIK: 0001561921

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Results of Operations and Financial Condition

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — tm2614218d1_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (tm2614218d1_ex99-1.htm)

EX-99.2 — EXHIBIT 99.2 (tm2614218d1_ex99-2.htm)

GRAPHIC (image_001.jpg)

GRAPHIC (tm2614218d1_ex99-2img001.jpg)

GRAPHIC (tm2614218d1_ex99-2img002.jpg)

GRAPHIC (tm2614218d1_ex99-2img003.jpg)

GRAPHIC (tm2614218d1_ex99-2img004.jpg)

GRAPHIC (tm2614218d1_ex99-2img005.jpg)

GRAPHIC (tm2614218d1_ex99-2img006.jpg)

GRAPHIC (tm2614218d1_ex99-2img007.jpg)

GRAPHIC (tm2614218d1_ex99-2img008.jpg)

GRAPHIC (tm2614218d1_ex99-2img009.jpg)

GRAPHIC (tm2614218d1_ex99-2img010.jpg)

GRAPHIC (tm2614218d1_ex99-2img011.jpg)

GRAPHIC (tm2614218d1_ex99-2img012.jpg)

GRAPHIC (tm2614218d1_ex99-2img013.jpg)

GRAPHIC (tm2614218d1_ex99-2img014.jpg)

GRAPHIC (tm2614218d1_ex99-2img015.jpg)

GRAPHIC (tm2614218d1_ex99-2img016.jpg)

GRAPHIC (tm2614218d1_ex99-2img017.jpg)

GRAPHIC (tm2614218d1_ex99-2img018.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2614218d1_8k.htm · Sequence: 1

false

0001561921

2026-05-12

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

May 12, 2026

TELA Bio, Inc.

(Exact name of registrant as specified in its

charter)

Delaware

001-39130

45-5320061

(State or other jurisdiction of

incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification No.)

1 Great Valley Parkway, Suite 24

Malvern, Pennsylvania

19355

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including

area code: (484) 320-2930

Not Applicable

(Former name or former address, if changed since

last report.)

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of

the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which

registered

Common Stock, par value $0.001 per share

TELA

Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth

company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities

Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant

has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant

to Section 13(a) of the Exchange Act. ¨

Item 2.02

Results of Operations and Financial Condition.

On May 12, 2026, TELA Bio, Inc. (the “Company”)

issued a press release announcing its financial results for the first quarter ended March 31, 2026. A copy of this press release is furnished

as Exhibit 99.1 hereto.

The information furnished pursuant to this Item 2.02, including Exhibit

99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange

Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference

in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except

as expressly set forth by specific reference in such filing.

Item 7.01

Regulation FD Disclosure.

On May 12, 2026, the Company updated information reflected in a corporate

slide deck, which representatives of the Company will use in various meetings with investors from time to time. A copy of the presentation

is attached hereto as Exhibit 99.2, and incorporated herein by reference.

The information furnished pursuant to Item 7.01, including Exhibit

99.2, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of

that section, and shall not be deemed to be incorporated by reference in any filing under the Securities Act or the Exchange Act, except

as expressly set forth by specific reference in such filing.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are being furnished herewith:

Exhibit No.

Document

99.1

Press Release of TELA Bio, Inc., dated May 12, 2026.

99.2

Corporate Slide Deck, dated May 12, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TELA BIO, INC.

By:

/s/ Antony Koblish

Name:

Antony Koblish

Title:

Chief Executive Officer and Director

Date: May 12, 2026

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: tm2614218d1_ex99-1.htm · Sequence: 2

Exhibit 99.1

TELA Bio Reports First Quarter 2026 Financial

Results

MALVERN, PA, May 12, 2026 -- TELA Bio, Inc.

(“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions,

today reported financial results for the first quarter ended March 31, 2026.

Recent Highlights

· Announced

strategic board refreshment plan to be effective at the conclusion of the 2026 Annual Meeting

on June 9, 2026;

· Noted

the U.S. commercial organization is fully staffed at planned 2026 levels;

· Delivered

revenue of $19.1 million in the first quarter of 2026, representing growth of 3% over the

prior year period;

· Accelerated

European revenue growth to 41% over the prior year period, with continued momentum in the

U.K. and early expansion into additional European markets;

· Announced

the U.S. commercial launch of OviTex LTR, providing a specialized, unique, and fully resorbable,

tissue-based hernia repair solution; and

· Reiterated

full year 2026 revenue guidance of at least 8% growth over full year 2025.

“First quarter results reflect the commercial foundation we

built in 2025 translating into execution,” said Anthony Koblish, Co-Founder and Chief Executive Officer of TELA Bio. “Our

commercial organization is fully built to plan, with no further hiring required to achieve our 2026 targets. The newest cohort of territory

managers is ramping as expected, and their early productivity indicators outpace any prior class of field reps. In Europe, our team is

gaining traction in new markets, with new accounts secured and first patients treated across multiple geographies. On April 1st, we initiated

the full U.S. commercial launch of OviTex LTR, one of the only fully resorbable, tissue-based hernia repair solutions on the market,

which further broadens the OviTex portfolio to address the full spectrum of surgeon and patient needs. The team is in place, the infrastructure

is set, and we are positioned well to deliver predictable growth through the remainder of 2026.”

First Quarter 2026 Financial Results

Revenue was $19.1 million in the first quarter of 2026, an increase

of 3% compared to the same period in 2025 with unit growth of 13% compared to the same period in 2025. The increase was primarily driven

by growing international sales, partially offset by product mix headwinds in the U.S. related to the rapid growth of smaller-sized units.

Gross profit was $12.5 million in the first quarter of 2026, or 65.7%

of revenue, compared to $12.5 million, or 67.6% of revenue, in the same period in 2025. The decrease in gross margin was primarily due

to a higher charge for excess and obsolete inventory as a percentage of revenue.

Operating expenses were $23.0 million in

both the first quarter of 2026 and 2025. There was a de minimis increase due to higher meeting and training costs and increased professional

fees partially offset by lower compensation and benefits primarily from lower commission expense, and lower study costs.

Loss from operations was $10.5 million in

both the first quarter of 2026 and 2025.

Net loss was $12.3 million in the first quarter

of 2026, compared to a net loss of $11.3 million in the same period in 2025.

Cash and cash equivalents on March 31, 2026

totaled $39.5 million.

2026 Financial Guidance Reiterated

· Full

year 2026 revenue growth is projected to be at least 8% over full year 2025; and

· Second quarter 2026 revenue is expected to be approximately

$20.0 million.

Conference Call

TELA Bio will host a conference call at 4:30

p.m. Eastern Time on Tuesday, May 12, 2026 to discuss its first quarter financial results. Investors interested in listening to the conference

call should register online. Participants are required to register a day in advance or at minimum 15 minutes before the start

of the call. A replay of the webcast can be accessed via the Events & Presentations page of the investor section of TELA Bio's

website.

About TELA Bio, Inc.

TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology

company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration

of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction

solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials.

For more information, visit www.telabio.com.

Caution Regarding Forward-Looking Statements

This press release contains forward-looking statements within the

meaning of The Private Securities Litigation Reform Act of 1995. Words such as “may,” “might,” “will,”

“should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,”

“predict,” “forecast,” “project,” “plan,” “intend” or similar expressions,

or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of TELA

Bio's management. Such forward-looking statements include statements relating to our expected revenue and revenue growth for the full

year 2026 and reduction in operating expenses throughout the full year 2026 compared to prior periods and our expectations regarding

new product launch and expectations on market penetration and profitability. These statements are not guarantees of future performance

and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and

adversely from those indicated by such forward-looking statements including, among others: the impact to our business from macroeconomic

conditions, including recessionary concerns, banking instability, increasing market interest rates, monetary policy changes, changes

in trade policies, including tariffs and trade protection measures, and inflationary pressures, potentially impacting our ability to

market our products, including the launch of new products; demand for our products related to changes in volumes or frequency of surgical

procedures, including due to outbreak of illness or disease, cybersecurity events impacting hospital operations, potential hospital closures,

labor and hospital staffing shortages, supply chain disruptions to critical surgical and hospital supplies, pricing pressures or any

other applicable adverse healthcare economic factors; our ability to achieve or sustain profitability; our ability to gain market acceptance

for our products and to accurately forecast and meet customer demand; our ability to compete successfully; that data from earlier studies

related to our products and interim data from ongoing studies may not be replicated in later studies or indicative of future data; that

data obtained from clinical studies using our product may not be indicative of outcomes in other surgical settings; our ability to enhance

our product offerings, including successful launch of new products; our ability to maintain expanded market access; product development

and manufacturing problems; capacity constraints or delays in production of our products; maintenance of coverage and adequate reimbursement

for procedures using our products; and product defects or failures. These risks and uncertainties are described more fully in the “Risk

Factors” section and elsewhere in our filings with the Securities and Exchange Commission and available at www.sec.gov, including

in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Any forward-looking statements that we make in this announcement

speak only as of the date of this press release, and TELA Bio assumes no obligation to update forward-looking statements whether as a

result of new information, future events or otherwise after the date of this press release, except as required under applicable law.

Investor Contact

Louisa Smith

ir@telabio.com

TELA Bio, Inc.

Consolidated Balance Sheets

(In thousands, except share and per share amounts)

(Unaudited)

March 31,

December 31,

2026

2025

Assets

Current assets:

Cash and cash equivalents

$ 39,541

$ 50,845

Accounts receivable, net of allowances of $424 and $287

9,715

10,347

Inventory

12,213

11,016

Prepaid expenses and other current assets

2,833

3,373

Total current assets

64,302

75,581

Property and equipment, net

2,157

2,226

Intangible assets, net

1,264

1,359

Right-of-use assets

1,442

1,502

Other long-term assets

476

500

Restricted cash

250

Total assets

$ 69,891

$ 81,418

Liabilities and stockholders’ (deficit) equity

Current liabilities:

Accounts payable

$ 3,894

$ 2,309

Accrued expenses and other current liabilities

13,939

15,666

Total current liabilities

17,833

17,975

Long-term debt

55,866

55,653

Other long-term liabilities

1,393

1,477

Total liabilities

75,092

75,105

Stockholders’ (deficit) equity:

Preferred stock; $0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding

—

Common stock; $0.001 par value: 200,000,000 shares authorized; 44,765,928 and 44,538,264 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively

Additional paid-in capital

404,503

403,739

Accumulated other comprehensive income

Accumulated deficit

(409,834 )

(397,561 )

Total stockholders’ (deficit) equity

(5,201 )

6,313

Total liabilities and stockholders’ (deficit) equity

$ 69,891

$ 81,418

TELA Bio, Inc.

Consolidated Statements of Operations and Comprehensive

Loss

(In thousands, except share and per share amounts)

(Unaudited)

Three months ended March 31,

2026

2025

Revenue

$ 19,059

$ 18,520

Cost of revenue (excluding amortization of intangible assets)

6,444

5,913

Amortization of intangible assets

Gross profit

12,520

12,512

Operating expenses:

Sales and marketing

16,537

16,608

General and administrative

4,166

3,836

Research and development

2,343

2,540

Total operating expenses

23,046

22,984

Loss from operations

(10,526 )

(10,472 )

Other (expense) income:

Interest expense

(2,053 )

(1,219 )

Other income

366

479

Total other expense, net

(1,687 )

(740 )

Loss before income tax expense

(12,213 )

(11,212 )

Income tax expense

(60 )

(52 )

Net loss

$ (12,273 )

$ (11,264 )

Net loss per common share, basic and diluted

$ (0.21 )

$ (0.25 )

Weighted average common shares outstanding, basic and diluted

57,256,518

45,267,020

Comprehensive loss:

Net loss

$ (12,273 )

$ (11,264 )

Foreign currency translation adjustment

(6 )

Comprehensive loss

$ (12,279 )

$ (11,263 )

EX-99.2 — EXHIBIT 99.2

EX-99.2

Filename: tm2614218d1_ex99-2.htm · Sequence: 3

Exhibit 99.2

INVESTOR PRESENTATION May 2026

This presentation contains forward - looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 . All statements other than statements of historical facts contained in this document, including but not limited to statements regarding possible or assu med future results of operations, business strategies, development plans, regulatory activities, market opportunity competitive position, potential growth oppo rtu nities, and the effects of competition, are forward - looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause the actual results, performance or achievements of TELA Bio, Inc. (the “Company”) to be materially different from any future res ults, performance or achievements expressed or implied by the forward - looking statements. In some cases, you can identify forward - looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “e sti mate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward - looking statements in this presentation are only predictio ns. The Company has based these forward - looking statements largely on its current expectations and projections about future events and financial trends th at it believes may affect the Company’s business, financial condition, and results of operations. These forward - looking statements speak only as of the date o f this presentation and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of whic h a re beyond the Company’s control, including, among others: the impact to our business from macroeconomic conditions, including recessionary concerns, ban king instability, increasing market interest rates, monetary policy changes, changes in trade policies, including tariffs and trade protection measures, a nd inflationary pressures, potentially impacting our ability to market our products; demand for our products related to changes in volumes or frequency of surgical procedures, including due to outbreak of illness or disease, cybersecurity events impacting hospital operations, potential hospital closures, labor an d hospital staffing shortages, supply chain disruptions to critical surgical and hospital supplies, pricing pressures or any other applicable adverse health car e economic factors; our ability to achieve or sustain profitability; our ability to gain market acceptance for our products and to accurately forecast and meet cus tomer demand; our ability to compete successfully; that data from earlier studies related to our products and interim data from ongoing studies may not be re plicated in later studies or indicative of future data; that data obtained from clinical studies using our product may not be indicative of outcomes in ot her surgical settings; our ability to enhance our product offerings; product development and manufacturing problems; capacity constraints or delays in production o f o ur products; maintenance of coverage and adequate reimbursement for procedures using our products; and product defects or failures. These and other ri sks and uncertainties are described more fully in the "Risk Factors" section and elsewhere in the Company's filings with the U.S. Securities and Exchan ge Commission (the “SEC”) and available at www.sec.gov . You should not rely on these forward - looking statements as predictions of future events. The events and circumstances reflecte d in the Company’s forward - looking statements may not be achieved or occur, and actual results could differ materially from those pro jected in the forward - looking statements. Moreover, the Company operates in a dynamic industry and economy. New risk factors and uncertainties may emerge f rom time to time, and it is not possible for management to predict all risk factors and uncertainties that the Company may face. Except as required by ap pli cable law, we do not plan to publicly update or revise any forward - looking statements contained herein, whether as a result of any new information, future ev ents, changed circumstances or otherwise. 2 Forward Looking Statements

We provide innovative soft - tissue reconstruction solutions that optimize clinical outcomes by prioritizing the Preservation and Restoration of the patient’s own anatomy. 3 Our Mission

TELA Bio, Inc. Advanced reinforced tissue matrix portfolio supported by compelling clinical evidence $2.6B US market opportunity 1 – still in early stages of growth Driving commercial adoption with targeted direct - sales approach Recent product launches in growing markets: robotic hernia surgery, plastic and reconstructive surgery Broad intellectual property portfolio Established DRG - based reimbursement pathway for hernia repair and robust GPO access Highly accomplished executive team with proven track record Redefining soft tissue preservation and restoration with a differentiated category of tissue reinforcement materials and supportive products 4 1. Management estimate. $2.6B total includes $1.8B hernia & abdominal wall reconstruction, $0.8B plastic reconstructive surgery.

Product Adoption Since Launch ~90,000 OviTex Reinforced Tissue Matrix (RTM) Implantations Globally 5 70+ Published or Presented Works ( OviTex + OviTex PRS) 5,000+ Hospitals Covered by GPO Access ~20,000 OviTex PRS Implantations (U.S.) 1,500 + Patients in Peer - Reviewed Publications

Complex, Moderate Ventral / Abdominal Wall Reconstruction Simple Ventral Hernia Repair Inguinal Hernia Repair Hiatal Hernia Repair ~105,000 ~395,000 ~645,000 ~42,000 $630 M $590 M $ 54 0 M $42 M 1. Sources: Millennium Research Group Reports, IMS Health Data; iData Research MedSKU . 2. Management estimate. Market size based on volume and weighted average selling price for OviTex . Annual Procedures 1 $1.8B 2 Robotic / Minimally Invasive Surgery (MIS) Opportunity within the Hernia Market Robotic / MIS compatible procedures total over 1M annually and have a potential market opportunity of up to $1.2B 2 7 ~$1.8 Billion Annual Opportunity US Hernia Surgery Market

OviTex Core 4 - layer device No smooth sides OviTex Core is designed to reinforce primary hernia repairs where the device will not come into contact with viscera . OviTex 1S 6 - layer device 1 smooth side OviTex 1S incorporates a smooth side that is designed to minimize tissue attachment and to reinforce primary hernia repairs where the device may come into contact with viscera (e.g. intraperitoneal). OviTex 2S 8 - layer device 2 smooth sides OviTex 2S incorporates eight layers of tissue for added strength. The two smooth sides make it suitable for intraperitoneal placement. OviTex Low Profile 4 - layer device 1 smooth side OviTex LPR is designed specifically for use in minimally invasive procedures. The design also incorporates a smooth side making it suitable for intraperitoneal placement. One Comprehensive Portfolio OviTex Inguinal 4 - layer and 3 - layer device No smooth sides OviTex IHR is designed specifically for use in inguinal hernia repair procedures. The design also incorporates an anatomical and rectangular shape to suit surgeon preference.

9 1. Hernia and Abdominal Surgeries Survey (Oct 2020). A group of 71 surgeons were surveyed regarding use of mesh in various he rni a repair surgeries. 2. Figures derived from Company - sponsored online poll of approximately 1,100 potential patients for hernia procedures. 3. See Medtronic plc Form 10 - Q, filed with the SEC on Aug. 27, 2024; Atrium Medical Corp. C - Qur Mesh Products Liability Litigation (Case No: 16 - md - 2753 LM); In RE: Ethicon Physiomesh Flexible Composite Hernia Mesh Products Liability Litigation (Case No: 1:17 - md - 02782 - RWS). 4. Reuters, “Becton Dickinson agrees to settle about 38,000 hernia mesh suits” (retrieved from https:// www.reuters.com /legal/litigation/becton - dickinson - agrees - settle - about - 38000 - hernia - mesh - suits - 2024 - 10 - 03/); Getinge Press Release, dated Decemb er 8, 2021; Johnson & Johnson Form 10 - K, filed with the SEC on February 16, 2024 regarding settlement of Ehticon Physiomesh Flexible Composite Mesh claims). 5. U.S. Food and Drug Administration. (n.d.). FDA's activities: Urogynecologic surgical mesh implants. U.S. Department of Health and Human Services. Retrieved from https:// www.fda.gov /news - events/press - announcements/fda - takes - action - protect - womens - health - orders - manufacturers - surgical - mesh - intended - transvaginal O f surgeons agree that use of permanent synthetic mesh puts patients at long - term risk of complications 1 59 % Hernia patients want proactive control in their care 2 3 of 4 Product liability lawsuits relating to permanent synthetic hernia repair (as of November 2024) 3 Not inclusive of ~40,000 or more cases settled or dismissed within the past three years 4 ~ 15,000 FDA issued multiple 522 orders to manufacturers requiring pre - market approval prior to sale and distribution of transvaginal mesh for pelvic organ prolapse repair 5 2019 Steps surgeons must take in the U.K. as part of the Royal College of Surgeons guidance for Patient Consent Supported Decision Making following the 2015 Montgomery Ruling 6 10 Need for Alternative to Permanent Synthetic Mesh

TELA Bio, the TELA Bio logo, and OviTex are each registered trademarks of TELA Bio, Inc. All other trademarks and trade names ar e the property of their respective owners or holders. *Overall complications including surgical site occurrences (SSOs) and surgical site infections (SSIs) a – OviTex patients were more complicated with a significantly higher mVHWG distribution and CDC wound classification compared to polypropylene patients. b – OviTex patients experienced significantly less complications than patients receiving the other three biologics. c – OviTex and Strattice patients had a statistically lower recurrence rate than patients receiving the other two biologics. Source: Refer to “Clinical References” in this presentation. Sivaraj et al. 2 Parker et al. 3 37 SurgiMend ® 17 Permacol TM 51 STRATTICE TM 36 OviTex 50 Polypropylene 50 OviTex Total enrolled patients 37.5 months (median) 58.4 months (median) 34.6 months (median) 28.6 months (median) 12 months 12 months Length of follow - up 40% grade 1 51% grade 2 9% grade 3 18% grade 1 71% grade 2 12% grade 3 17% grade 1 79% grade 2 4% grade 3 33% grade 1 58% grade 2 8% grade 3 94% grade 2 6% grade 3 32% grade 2 68% grade 3 a mVHWG 91% class I - II 94% class I - II 86% class I - II 89% class I - II 94% CDC class I 70% CDC class II+ a CDC wound class 43.2%* 52.9%* 47.1%* 16.7%* 22%* 36%* Incidence of SSO 5.4% 11.8% 12.5% 2.8% b - - Incidence of SSI 24.3% 29.4% 13.7% c 2.8% c 12% 6% Recurrence rate 11 Comparisons to synthetic mesh and leading first generation biologics Favorable Results of OviTex in Ventral Hernia Repair

TELA Bio, the TELA Bio logo, and OviTex are each registered trademarks of TELA Bio, Inc. All other trademarks and trade names ar e the property of their respective owners or holders. * Kaplan - Meier survival estimate **No head - to - head clinical studies have been conducted. Due to differences in patient population, surgeons, surgical technique, and other variables, no direct comparisons of results can be made. For a comparative discussion of these studies, please see G. DeNoto, E.P. Ceppa , S.J. Pacella, M. Sawyer, G. Slayden, M. Takata, G. Tuma, J. Yunis, 24 - Month results of the BRAVO study: A prospective, multi - c enter study evaluating the clinical outcomes of a ventral hernia cohort treated with OviTex® 1S permanent reinforced tissue matrix, Ann Medicine Surg 2022, 83, 104745 . Hope et al. (ATLAS) 13 Roth et al. 12 Harris et al. (PRICE) 11 DeNoto et al. (BRAVO) 4 120 Phasix TM ST 121 Phasix TM 83 Ventralight TM ST or Bard Soft Mesh 82 STRATTICE TM 92 OviTex Total enrolled patients 24 months 36 months 26 months 24 months Length of follow - up - - - 78% grade 2 - 3 mVHWG 100% class I 100% class I 93% class l - ll 90% class l - ll 95% class I - II CDC wound class Laparoscopic (55.8%) Robotic (44.2%) Open Open Open Open (65%) Laparoscopic (13%) Robotic (22%) Surgical technique 0.8% (includes SSI) - 22% (excludes SSI) 21% (excludes SSI) 38% (includes SSI) Incidence of SSO 0% 9% * 34% 39% 20.7% Incidence of SSI 31.7% * (overall) 18.6% * (defects < 7cm 2 ) 17.9% * 22% (overall) 28% (class I wounds) 40% (overall) 34% (class I wounds) 2.6% * Recurrence rate Source: Refer to “Clinical References” in this presentation. 12 OviTex performance contextualized alongside contemporaneous publications for leading competitive products Positive 24 - month BRAVO Results In Ventral Hernia

TELA Bio positioned to grow from a market shift towards resorbable and more “natural repair” solutions as an alternative to traditional permanent synthetics or biologics Hernia Market Evolution 2027 2021 2018 2013 Permanent Synthetic Biologic Sales Market Share <1% Robotic Procedures ( Px ) 7% Robotic Px 12% Robotic Px 202 3 1 4 % Robotic Px Resorbable Synthetics Reinforced Tissue Matrix 21% Robotic Px Resorbable Synthetics and Reinforced Tissue Matrix strengths: 13 Sources for Sales Market Share (%): 2009 - 2013 = IMS Hospital Supply Index; 2018 - 2023 = iData Research MedSKU Sources for Total U.S. Market Size: 2021 - 202 7 = DRG Hernia Repair Devices Report – 2021; 2013 - 2018 = Management Estimate. Sources for % Robotic Procedures: 2018 - 2027 = DRG Hernia Repair Devices Report – 2021; 2013 = Management Estimate. Clinical Evidence Robot Compatibility Cost - effectiveness Patient Choice & Shared Decision - making

14 Multiple Layers of Ovine Rumen Three Polymer Options

15 ~$800 Million Annual Opportunity US Plastic & Reconstructive Surgery Market $700M 2 1. OviTex PRS is for implantation to reinforce soft tissue where weakness exists in patients requiring soft tissue repair or reinforcem en t in plastic and reconstructive surgery. The device is supplied sterile and is intended for one - time use. OviTex PRS has not been tested in breast surgical procedures. 2. Management estimate. Source: iData Research MedSKU , Q1 2024. Market size based on sales of current biologics. + $100M 2 Cosmetic Plastic & Reconstructive Surgery Market dominated by human acellular dermal matrices (HADMs): Prone to high degree of stretch Expensive, putting pressure on hospital systems Can experience supply shortages, particularly when large pieces of material are required

Specifically designed for plastic and reconstructive surgery OviTex PRS An innovative reinforced tissue matrix designed to improve outcomes by facilitating fluid management and controlling degree and direction of stretch Product Features: Layers composed of biologic building block retain biologically significant macromolecules for tissue regeneration 1,2 Diamond embroidery pattern and stents allow for directional flexibility; sawtooth embroidery pattern and slits allow for bi - directional stretch while providing stretch resistance Distinct permeability elements in various configurations – e.g., micropores, macropores, and stents/slits – designed to facilitate fluid management OviTex PRS compared to market leading human ADM 3 Exhibited earlier host cell proliferation, collagen deposition and neovascularization Demonstrated tissue remodeling into mature, functional and organized collagen 1. Certain configurations available in two or three layers, see product catalog more information. 2. Lun S, Irvine S.M., John son K.D., Fisher N.J., Floden E. W., Negron L., Dempsey S.G. , McLaughlin R.J., Vasudevamurthy M. , Ward B.R., May B.C., A functional extracellular matrix biomaterial derived from ovine forestomach, Biomaterials 31(16) (2010) 4517 - 29. 3. ADM: Acellular Dermal Matrix. Overbeck N, Beierschmitt A, May BC, Qi S, Koch J. In - Vivo Evaluation of a Reinforced Ovine Biologic for Plastic and Reconstructive Procedures in a Non - human Primate Model of Soft Tissue Repair. Eplasty . 2022 Sep 14;22:e43. PMID: 36160663; PMCID: PMC9490877. Animal testing results may not be indicative of clinical performance. 16 Available in 2 - layer resorbable (polyglycolic acid) polymer, 3 - layer permanent (polypropylene) polymer, or 3 - layer resorbable (polylactic - co - glycolic acid) polymer reinforcing the same biologic material

17 Leading - edge atraumatic hernia mesh fixation devices Designed to minimize complications for patient safety and comfort

LIQUIFIX FIX8 & LIQUIFIX Precision Atraumatic liquid fixation devices Reduce the need for penetrating mechanical fixation for inguinal and femoral hernia repair Provide precise, controlled adhesive application Addresses an unmet need in the market, less damage to tissue Designed to minimize the risk of mechanical tissue trauma 2 Strong and secure mesh fixation 2 Pre - assembled device Adhesives polymerize in ~10 seconds Provides versatile liquid anchors at multiple angles 1 . The LIQUIFIX FIX8 device is intended for use in minimally invasive surgical repair of groin (inguinal and femoral) hernias (including both laparoscopic and robotic - assisted techniques), achieved through the fixation of prosthetic polypropylene or polyester mesh to the abdominal wall and the approximation of the peritoneum. The LIQUIFIX Precision device is intended for use in open surgical repair of groin (inguinal and femoral) hernias, achieved through the fixation of prosthetic polypropylene or polyester mesh to the abdominal wall. 18 LIQUIFIX is the only FDA - approved device that affixes mesh and peritoneal tissue with liquid anchors, indicated for minimally invasive and open inguinal and femoral hernia repairs.

19 20 +45% +39% +35% +46% +39% +11% +26% +4% +12% +26% +9% +18% +3% 60% 65% 70% 75% 80% $0 $5 $10 $15 $20 $25 1Q23 2Q23 3Q23 4Q23 1Q24 2Q24 3Q24 4Q24 1Q25 2Q25 3Q25 4Q25 1Q26 Gross Margin Revenue ($M) Quarterly Revenue and Gross Margin Revenue Gross Margin $58.5M, +41% $69.3M, +19% $80.3M, +16%

21 Delivering Revenue Growth and Strong Margin with Continuing Improvement Potential $19M Quarterly revenue of $19.1M, growing 3% over corresponding period of 2025 $ 39 .5M Cash and Cash Equivalents at March 31, 2026 66% Gross Margin Q1 2026 Performance

GRAPHIC

Filename: image_001.jpg · Sequence: 4

Binary file (5390 bytes)

Download image_001.jpg

GRAPHIC

Filename: tm2614218d1_ex99-2img001.jpg · Sequence: 8

Binary file (107685 bytes)

Download tm2614218d1_ex99-2img001.jpg

GRAPHIC

Filename: tm2614218d1_ex99-2img002.jpg · Sequence: 9

Binary file (413488 bytes)

Download tm2614218d1_ex99-2img002.jpg

GRAPHIC

Filename: tm2614218d1_ex99-2img003.jpg · Sequence: 10

Binary file (182341 bytes)

Download tm2614218d1_ex99-2img003.jpg

GRAPHIC

Filename: tm2614218d1_ex99-2img004.jpg · Sequence: 11

Binary file (224082 bytes)

Download tm2614218d1_ex99-2img004.jpg

GRAPHIC

Filename: tm2614218d1_ex99-2img005.jpg · Sequence: 12

Binary file (254677 bytes)

Download tm2614218d1_ex99-2img005.jpg

GRAPHIC

Filename: tm2614218d1_ex99-2img006.jpg · Sequence: 13

Binary file (171317 bytes)

Download tm2614218d1_ex99-2img006.jpg

GRAPHIC

Filename: tm2614218d1_ex99-2img007.jpg · Sequence: 14

Binary file (185967 bytes)

Download tm2614218d1_ex99-2img007.jpg

GRAPHIC

Filename: tm2614218d1_ex99-2img008.jpg · Sequence: 15

Binary file (192620 bytes)

Download tm2614218d1_ex99-2img008.jpg

GRAPHIC

Filename: tm2614218d1_ex99-2img009.jpg · Sequence: 16

Binary file (181799 bytes)

Download tm2614218d1_ex99-2img009.jpg

GRAPHIC

Filename: tm2614218d1_ex99-2img010.jpg · Sequence: 17

Binary file (181481 bytes)

Download tm2614218d1_ex99-2img010.jpg

GRAPHIC

Filename: tm2614218d1_ex99-2img011.jpg · Sequence: 18

Binary file (178032 bytes)

Download tm2614218d1_ex99-2img011.jpg

GRAPHIC

Filename: tm2614218d1_ex99-2img012.jpg · Sequence: 19

Binary file (158781 bytes)

Download tm2614218d1_ex99-2img012.jpg

GRAPHIC

Filename: tm2614218d1_ex99-2img013.jpg · Sequence: 20

Binary file (163964 bytes)

Download tm2614218d1_ex99-2img013.jpg

GRAPHIC

Filename: tm2614218d1_ex99-2img014.jpg · Sequence: 21

Binary file (269010 bytes)

Download tm2614218d1_ex99-2img014.jpg

GRAPHIC

Filename: tm2614218d1_ex99-2img015.jpg · Sequence: 22

Binary file (181458 bytes)

Download tm2614218d1_ex99-2img015.jpg

GRAPHIC

Filename: tm2614218d1_ex99-2img016.jpg · Sequence: 23

Binary file (191350 bytes)

Download tm2614218d1_ex99-2img016.jpg

GRAPHIC

Filename: tm2614218d1_ex99-2img017.jpg · Sequence: 24

Binary file (117582 bytes)

Download tm2614218d1_ex99-2img017.jpg

GRAPHIC

Filename: tm2614218d1_ex99-2img018.jpg · Sequence: 25

Binary file (121063 bytes)

Download tm2614218d1_ex99-2img018.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 27

v3.26.1

Cover

May 12, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

May 12, 2026

Entity File Number

001-39130

Entity Registrant Name

TELA Bio, Inc.

Entity Central Index Key

0001561921

Entity Tax Identification Number

45-5320061

Entity Incorporation, State or Country Code

Entity Address, Address Line One

1 Great Valley Parkway

Entity Address, Address Line Two

Suite 24

Entity Address, City or Town

Malvern

Entity Address, State or Province

Entity Address, Postal Zip Code

19355

City Area Code

484

Local Phone Number

320-2930

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value $0.001 per share

Trading Symbol

TELA

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration